Angiogenic tumor endothelial cell membrane (TEC membrane)

The angiogenic tumor endothelial cell membrane refers to the specialized surface of endothelial cells within the tumor microenvironment that are actively involved in neovascularization (Source: PubMed, PMID: 12154373). This membrane is distinct from that of quiescent endothelial cells, as it overexpresses a variety of functional proteins including Vascular Endothelial Growth Factor Receptor 2 (VEGFR2), integrins (specifically alpha-v beta-3), and Endoglin (CD105) (Source: NIH, National Cancer Institute). These proteins serve as critical mediators of tumor angiogenesis, facilitating the growth and survival of the tumor by ensuring a steady supply of oxygen and nutrients (Source: StatPearls, Angiogenesis Inhibitors). Therapeutically, the membrane is targeted by monoclonal antibodies, small molecule inhibitors, and ligand-directed delivery systems to disrupt tumor blood flow or deliver cytotoxic agents directly to the vasculature (Source: PubMed, PMID: 25605325). Common drugs interacting with components of this membrane include Ramucirumab and various integrin antagonists (Source: FDA, Cyramza Label). However, targeting this site is associated with specific safety concerns such as hypertension, hemorrhage, and impaired wound healing due to the inhibition of physiological angiogenesis (Source: PubMed, PMID: 17000677).

Other names

Tumor endothelial cell surfaceTumor neovasculature membraneAngiogenic endotheliumTumor-associated endothelial cell membrane

Inhibition of receptor-mediated signaling (e.g., VEGFR2), disruption of cell-matrix adhesion (e.g., integrin blockade), and targeted delivery of therapeutic payloads to the tumor vasculature.